![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC5A9 |
Gene summary for SLC5A9 |
![]() |
Gene information | Species | Human | Gene symbol | SLC5A9 | Gene ID | 200010 |
Gene name | solute carrier family 5 member 9 | |
Gene Alias | SGLT4 | |
Cytomap | 1p33 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q2M3M2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
200010 | SLC5A9 | HCC1_Meng | Human | Liver | HCC | 7.63e-17 | 5.38e-02 | 0.0246 |
200010 | SLC5A9 | HCC1 | Human | Liver | HCC | 2.57e-02 | 2.05e+00 | 0.5336 |
200010 | SLC5A9 | HCC2 | Human | Liver | HCC | 3.37e-08 | 2.20e+00 | 0.5341 |
200010 | SLC5A9 | Pt14.a | Human | Liver | HCC | 2.60e-02 | 2.57e-01 | 0.0169 |
200010 | SLC5A9 | S015 | Human | Liver | HCC | 1.52e-10 | 3.75e-01 | 0.2375 |
200010 | SLC5A9 | S016 | Human | Liver | HCC | 1.75e-05 | 2.35e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC5A9 | SNV | Missense_Mutation | c.1666N>A | p.Leu556Met | p.L556M | Q2M3M2 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
SLC5A9 | SNV | Missense_Mutation | c.635N>G | p.Tyr212Cys | p.Y212C | Q2M3M2 | protein_coding | deleterious(0.01) | benign(0.25) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
SLC5A9 | SNV | Missense_Mutation | c.1449N>A | p.Asp483Glu | p.D483E | Q2M3M2 | protein_coding | tolerated(0.36) | benign(0.41) | TCGA-E2-A15G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
SLC5A9 | insertion | Frame_Shift_Ins | novel | c.993_994insGGGGTCAGGTCCCAGG | p.Ser332GlyfsTer52 | p.S332Gfs*52 | Q2M3M2 | protein_coding | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
SLC5A9 | SNV | Missense_Mutation | novel | c.1580T>C | p.Leu527Pro | p.L527P | Q2M3M2 | protein_coding | deleterious(0.03) | benign(0.418) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC5A9 | SNV | Missense_Mutation | rs756014240 | c.46G>A | p.Gly16Arg | p.G16R | Q2M3M2 | protein_coding | tolerated_low_confidence(0.22) | benign(0) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SLC5A9 | SNV | Missense_Mutation | c.634N>C | p.Tyr212His | p.Y212H | Q2M3M2 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC5A9 | SNV | Missense_Mutation | c.1424N>T | p.Ser475Ile | p.S475I | Q2M3M2 | protein_coding | deleterious(0.03) | benign(0.261) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
SLC5A9 | SNV | Missense_Mutation | c.109G>A | p.Asp37Asn | p.D37N | Q2M3M2 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC5A9 | SNV | Missense_Mutation | rs149305292 | c.1816G>A | p.Glu606Lys | p.E606K | Q2M3M2 | protein_coding | tolerated(0.33) | benign(0.001) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |